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Familial Associations of Colorectal 
Cancer with Other Cancers
Hongyao Yu1, Akseli Hemminki2,3, Kristina Sundquist4 & Kari Hemminki1,4
Colorectal cancer (CRC) has a strong familial component which extends to discordant cancers (ie non-
CRC tumors). This is best seen in cancer syndromes such as hereditary non-polyposis colorectal cancer 
(HNPCC) which predisposes to several tumor types. Population-based family studies have also found 
discordant associations for CRC but they have included cancers which manifest in HNPCC, and there is 
no convincing evidence of discordant associations beyond the known syndromes. We address familial 
associations of non-CRC tumors with CRC using the resources of the Swedish Family-Cancer Database 
and applying a powerful approach of assessing familial relative risks in families of increasing numbers 
of patients with discordant cancers. Among 1.8 million cancer patients and over 200,000 CRC cases 
consistent familial associations of CRC was observed for several HNPCC related cancers. However, for 
small intestinal, pancreatic and nervous system cancers RRs remained essentially unchanged when 
potential HNPCC families were excluded, suggesting involvement of genes not related to HNPCC. 
Two independent associations of CRC were found for melanoma, thyroid and eye cancers and these 
appeared not to be related to known syndromes. A number of other cancers associated with CRC in 
single analyses and independent studies are required to assess the relevance of such findings.
About 13% of patients with colorectal cancer (CRC) have a parent or a sibling diagnosed with CRC and the 
familial relative risks (RRs) are 1.80 and 2.00, respectively1, 2. Risks between spouses have been less than 1.10, 
suggesting that familial clustering can mostly be explained by genetic susceptibility. Hereditary non-polyposis 
colorectal cancer (HNPCC) is the most common CRC syndrome, accounting for some 10% of familial CRC3, 
4 (for distinction between HNPCC and Lynch syndrome see Methods). Exome sequencing of 625 early-onset 
familial CRC cases found deleterious mutations in 89 (14%) patients, mismatch repair gene mutations being the 
most common (76.4%), followed by APC (11.2%), MUTYH (7.9%) and POLE and POLD1 (3.4%)3. However, 
variants of uncertain relevance may increase this figure if they are found to be deleterious3, 5. Additionally, numer-
ous (at least 50) low-risk susceptibility loci have been identified6. However, as their RRs are low they combined 
contribute to the familial risk no more than the high-risk genes7. Thus, known genes appear to explain less than 
30% of the empirical familial risk of CRC.
HNPCC, familial adenomatous polyposis (FAP) and other rare CRC-related cancer syndromes manifest also 
cancers other than CRC; in HNPCC the risk of at least 8 cancers is increased4, 8, 9. Also population-based family 
studies have shown shared association of CRC and a few other cancers, such as endometrial and pancreatic can-
cers10, 11. Data for associated discordant (i.e., other) cancers may provide clues about shared genetic pathways or 
environmental risk factors of these cancer and CRC.
We use here stringent statistical criteria to search for discordant familial associations with CRC and other 
cancers using the most recent update of the Swedish Family-Cancer Database, the largest family dataset in the 
world12. The approach involves a two-way comparison, i.e., assessment of familial RRs for cancer X in families 
with increasing numbers of patients with CRC, or conversely, familial RRs for CRC in families with increasing 
numbers of patients with cancer X. As HNPCC manifests many different cancers we wanted to test if discordant 
associations are found if the number if HNPCC families were reduced, by removing any families presenting dou-
ble primaries of typical HNPCC related cancers9, 13.
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Results
The nationwide Swedish Family-Cancer Database includes 4.3 million families and 1.8 million cancers reported 
to the national Cancer Registry. A total of 207,512 individuals were diagnosed with CRC, and of these 35,360 
were in the 0–80 year old offspring generation used as index individuals to calculate RRs. Exclusion of potential 
HNPCC families (see Methods), removed 16,160 (0.37%) families, including 41,201 individuals without cancer 
and 22,656 cancer patients.
In Table 1 all cancers are shown which were significantly associated with CRC in any of two-way comparisons 
(even considering the trend test), including 14 discordant cancers. As reference we show RRs for concordant 
CRC which increased from 1.76 (1 proband diagnosed with CRC) to 5.13 (at least 3 probands diagnosed with 
CRC). All RRs were significant at 0.1% confidence levels. Considering significant trend tests for both of the 
two-way analyses, small intestinal, pancreatic, endometrial, ovarian and nervous system cancers showed consist-
ent increases. However, with the exception of endometrial cancers, almost all significant associations were limited 
to families of one affected proband. For thyroid cancer, 3 RRs were increase, for eye cancer 2 RRs were increased 
and for the remaining cancers only one RR was increased. The exception was stomach cancers for which only one 
trend test was increased. The mean age at diagnosis for CRC in thyroid cancer families was 59.3 years compared to 
58.7 years in all CRC; the 5 CRCs with an RR of 4.28 (2 thyroid cancers in probands) were diagnosed at the mean 
age of 61.4 years. We looked in more detail on eye cancer histology: half of the cases were ocular melanomas but 
none of the RRs for this histological type reached statistical significance.
Table 2 shows data for CRC associations when double primaries of potential HNPCC related cancers were 
removed. RRs for concordant CRC remained highly significant although they were decreased compared to 
Table 1. For endometrial and ovarian cancer almost all significant associations disappeared. For stomach can-
cer the trend test was no longer significant and for prostate cancer the single significant RR lost its significance, 
even though the magnitudes of RRs did not essentially change. For the other cancers RRs remained essentially 
unchanged between Tables 1 and 2, and for melanoma two RRs were significant compared to one RR in Table 1.
Risk in offspring Proband cancer
1 cancer case in the family 2 cancer cases in the family >=3 cancer cases in the family Trend test
Cases RR1 95% CI2 Cases RR 95% CI Cases RR 95% CI P-value
Stomach Colorectum 479 1.09 (0.99–1.21) 29 1.38 (0.93–2.05) 3 2.56 (0.76–8.64) 0.02696
Colorectum Stomach 1178 1.06 (0.81–1.37) 23 1.35 (0.22–8.36) 0 . . 0.6672
Small intestine Colorectum 185 1.284 (1.10–1.49) 11 1.65 (0.90–3.00) 2 6.003 (1.48–24.33) 0.0007
Colorectum Small intestine 160 1.33 (1.11–1.59) 0 . . 0 . . 0.0026
Colorectum Colorectum 4786 1.765 (1.70–1.82) 381 2.93 (2.60–3.30) 36 5.13 (3.48–7.54)  < 0.0001
Pancreas Colorectum 612 1.13 (1.03–1.25) 35 1.33 (0.90–1.97) 3 1.96 (0.52–7.49) 0.0040
Colorectum Pancreas 861 1.15 (1.07–1.23) 13 1.52 (0.87–2.63) 0 . . <0.0001
Lung Colorectum 2159 1.07 (1.00–1.14) 101 1.03 (0.77–1.37) 4 0.71 (0.17–3.01) 0.0621
Colorectum Lung 1972 1.07 (1.02–1.13) 70 1.09 (0.84–1.42) 3 1.02 (0.29–3.61) 0.0082
Breast Colorectum 6507 1.06 (1.01–1.10) 300 1.08 (0.89–1.31) 11 0.82 (0.29–2.27) 0.0158
Colorectum Breast 3278 1.03 (0.99–1.08) 185 1.09 (0.93–1.29) 5 0.52 (0.19–1.42) 0.0999
Endometrium Colorectum 1025 1.09 (1.00–1.19) 68 1.47 (1.07–2.03) 4 1.62 (0.43–6.07) 0.0098
Colorectum Endometrium 912 1.21 (1.12–1.32) 21 2.22 (1.32–3.73) 0 . . <0.0001
Ovary Colorectum 861 1.10 (1.02–1.19) 40 1.12 (0.78–1.60) 4 2.15 (0.70–6.64) 0.0237
Colorectum Ovary 685 1.09 (1.01–1.18) 6 1.00 (0.44–2.27) 0 . . 0.0252
Prostate Colorectum 5451 1.02 (0.99–1.05) 253 0.99 (0.86–1.14) 13 1.01 (0.54–1.90) 0.3625
Colorectum Prostate 3887 1.04 (1.01–1.08) 266 1.12 (0.98–1.28) 16 0.65 (0.38–1.12) 0.0176
Melanoma Colorectum 2249 1.06 (1.00–1.12) 117 1.30 (1.02–1.66) 5 1.23 (0.38–4.04) 0.0149
Colorectum Melanoma 839 1.04 (0.96–1.12) 28 1.50 (0.99–2.28) 2 3.40 (0.71–16.28) 0.1458
Eye Colorectum 136 1.20 (1.01–1.41) 10 2.11 (1.17–3.79) 1 4.39 (0.69–27.74) 0.0050
Colorectum Eye 76 0.94 (0.70–1.25) 0 . . 0 . . 0.6596
Nervous system Colorectum 1568 1.09 (1.03–1.15) 71 1.19 (0.93–1.52) 6 2.10 (0.90–4.89) 0.0011
Colorectum Nervous system 885 1.14 (1.06–1.24) 8 0.74 (0.33–1.65) 1 4.25 (0.44–41.53) 0.0041
Thyroid gland Colorectum 442 1.16 (1.05–1.28) 24 1.54 (1.02–2.33) 0 . . 0.0009
Colorectum Thyroid gland 226 1.05 (0.93–1.19) 5 4.28 (1.85–9.91) 0 . . 0.2262
Myeloma Colorectum 393 1.17 (1.06–1.29) 23 1.44 (0.98–2.14) 1 1.21 (0.18–7.92) 0.0006
Colorectum Myeloma 427 1.06 (0.96–1.17) 3 0.93 (0.29–2.99) 0 . . 0.2603
CUP7 Colorectum 747 1.01 (0.88–1.15) 52 1.46 (0.89–2.39) 2 0.97 (0.08–12.08) 0.5309
Colorectum CUP 1012 1.14 (1.05–1.24) 13 1.46 (0.69–3.09) 0 . . 0.0027
Table 1. Discordant and concordant risks for CRC. 1RR = relative risk. 2CI = confidence interval. 3Bold type 
denotes significantly increased RR at the two-sided 5% level. 4Bold and underlined value denotes significantly 
increased RR at the two-sided 1% level. 5Bold, underlined and Italics value denotes significantly increased RR 
at the two-sided 0.1% level. 6Bold type denotes that trend test was statistically significant. 7CUP = cancer of 
unknown primary.
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Discussion
The present study has unsurpassed statistical power to tell which cancers are associated with CRC but multiple 
comparisons are an unavoidable concern in exploratory studies of the present kind. The present design assumed 
that for a true familial association more than a single analysis should be positive and RRs should optimally show 
a ‘dose-response’, i.e., increase by the number of affected probands, beautifully shown for concordant CRC. 
Endometrial, small intestinal and thyroid cancers showed 3 significant RRs of which some were at 1% or higher 
confidence level, pancreatic and nervous system cancers showed 2 increased RR of which one was highly signifi-
cant (<0.1%), and ovarian and eye cancers showed 2 RRs with nominal significance. Lung cancer, myeloma and 
CUP showed a single significant RR with a 1% confidence level. The remaining cancers showed a single nomi-
nal significance; however melanoma showed two associations when potential HNPCC families were removed. 
Stomach cancer was not association with CRC but showed one positive trend test. There are formal methods of 
adjustment for multiple comparisons, such as the Bonferroni correction. However, this correction is not very 
suitable for the present data with several test units of finite number of samples. We would consider two inde-
pendent significant associations persuasive, as was the case for ovarian cancers which is known to be a common 
manifestation in HNPCC8, 14.
One of the aims of the study was to assess if familial associations could be found outside known CRC related 
cancer syndromes. The attempt to remove HNPCC families could of course not be fully effective (see next par-
agraph), for example because of small families, but it showed decreases in RRs and significance levels, particu-
larly for endometrial and ovarian cancers. However, RRs remained essentially unchanged for some cancer types 
considered HNPCC related, such as small intestinal, pancreatic and central nervous system cancers, leaving the 
option that the associations were not driven by HNPCC. Thus, for endometrial and ovarian, much of the associ-
ation with CRC seemed to relate to HNPCC while for the other tumor types the genetics could be more complex.
The present study was nation-wide and we had no access to genetic data which would ethically very sensitive. 
However, to put the scope of our study in perspective, a recent study reported that 369 Lynch syndrome families 
Risk in offspring Proband cancer
1 cancer case in the family 2 cancer cases in the family >=3 cancer cases in the family Trend test
Cases RR1 95% CI2 Cases RR 95% CI Cases RR 95% CI P-value
Stomach Colorectum 451 1.09 (0.98–1.21) 22 1.20 (0.76–1.90) 3 3.39 (0.98–11.70) 0.0644
Colorectum Stomach 1092 1.05 (0.80–1.38) 23 1.45 (0.23–9.11) 0 . . 0.6927
Small intestine Colorectum 167 1.254 (1.06–1.47) 8 1.40 (0.68–2.87) 2 8.233 (1.96–34.47) 0.00656
Colorectum Small intestine 143 1.31 (1.09–1.59) 0 . . 0 . . 0.0070
Colorectum Colorectum 4080 1.685 (1.62–1.74) 282 2.63 (2.29–3.01) 18 3.73 (2.19–6.36) <0.0001
Pancreas Colorectum 573 1.13 (1.02–1.25) 30 1.31 (0.85–2.01) 1 0.87 (0.08–9.18) 0.0141
Colorectum Pancreas 811 1.16 (1.08–1.25) 12 1.50 (0.84–2.68) 0 . . <0.0001
Lung Colorectum 2023 1.06 (0.99–1.14) 91 1.06 (0.77–1.45) 2 0.48 (0.06–3.97) 0.0890
Colorectum Lung 1827 1.07 (1.01–1.12) 66 1.11 (0.85–1.46) 3 1.09 (0.31–3.87) 0.0154
Breast Colorectum 6090 1.05 (1.00–1.10) 254 1.05 (0.84–1.31) 8 0.78 (0.23–2.72) 0.0388
Colorectum Breast 3051 1.03 (0.99–1.08) 170 1.08 (0.92–1.28) 3 0.34 (0.10–1.17) 0.1068
Endometrium Colorectum 898 1.03 (0.93–1.15) 50 1.26 (0.82–1.96) 2 1.10 (0.12–9.76) 0.3570
Colorectum Endometrium 751 1.10 (1.01–1.21) 15 1.80 (0.95–3.41) 0 . . 0.0250
Ovary Colorectum 771 1.06 (0.99–1.14) 32 1.04 (0.74–1.46) 2 1.44 (0.37–5.57) 0.1083
Colorectum Ovary 619 1.08 (1.00–1.17) 6 1.09 (0.48–2.48) 0 . . 0.0611
Prostate Colorectum 5147 1.02 (0.99–1.05) 209 0.94 (0.80–1.10) 8 0.89 (0.39–2.01) 0.4966
Colorectum Prostate 3608 1.04 (1.00–1.08) 238 1.08 (0.94–1.24) 13 0.57 (0.32–1.02) 0.0534
Melanoma Colorectum 2101 1.05 (1.00–1.11) 104 1.33 (1.06–1.67) 3 1.00 (0.26–3.84) 0.0096
Colorectum Melanoma 782 1.04 (0.96–1.13) 27 1.56 (1.01–2.40) 2 3.70 (0.76–18.05) 0.1267
Eye Colorectum 127 1.19 (1.00–1.42) 8 1.94 (1.00–3.77) 1 5.87 (0.90–38.35) 0.0151
Colorectum Eye 73 0.97 (0.77–1.21) 0 . . 0 . . 0.7708
Nervous system Colorectum 1454 1.08 (1.02–1.14) 57 1.10 (0.83–1.45) 5 2.35 (0.92–6.01) 0.0089
Colorectum Nervous system 815 1.14 (1.05–1.24) 6 0.60 (0.23–1.55) 1 4.55 (0.44–47.13) 0.0101
Thyroid gland Colorectum 410 1.15 (1.03–1.28) 18 1.33 (0.82–2.16) 0 . . 0.0064
Colorectum Thyroid gland 214 1.07 (0.94–1.22) 4 3.77 (1.46–9.71) 0 . . 0.1845
Myeloma Colorectum 370 1.17 (1.05–1.30) 20 1.44 (0.93–2.24) 1 1.64 (0.23–11.71) 0.0018
Colorectum Myeloma 397 1.06 (0.96–1.17) 3 1.00 (0.31–3.21) 0 . . 0.2834
CUP7 Colorectum 699 1.00 (0.87–1.15) 45 1.44 (0.84–2.49) 2 1.28 (0.10–16.87) 0.6307
Colorectum CUP 950 1.15 (1.05–1.26) 13 1.58 (0.74–3.37) 0 . . 0.0022
Table 2. Discordant and concordant risks for CRC in non-HNPCC families. 1RR = relative risk. 
2CI = confidence interval. 3Bold type denotes significantly increased RR at the two-sided 5% level. 4Bold and 
underlined value denotes significantly increased RR at the two-sided 1% level. 5Bold, underlined and Italics 
wvalue denotes significantly increased RR at the two-sided 0.1% level. 6Bold type denotes that trend test was 
statistically significant. 7CUP = cancer of unknown primary.
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were identified in Sweden but no information was given on how many persons were tested for mutations15. The 
authors estimated that no more than one-quarter of the mutation carriers had been identified in Sweden which 
may imply that some 1500 Lynch syndrome families would exist. Thus our exclusion of 16,160 potential HNPCC 
families probably included a good proportion of Swedish Lynch syndrome families. However, similar exclusion of 
families carrying APC, MUTYH or POLE and POLD1 mutations because known cancers other than CRC are rare 
or unknown in these syndrome, and exclusion based on CRC would have defeated the purpose.
The associations of CRC with melanoma, thyroid and eye cancers appeared not to be related to known syn-
dromes. Papillary thyroid cancer, the most common of thyroid cancers, is known to manifest in FAP but CRCs 
in this syndrome are early onset while the present CRCs associated with thyroid cancer were diagnosed at some-
what higher age than CRCs overall16. In a recent study on familial and multiple melanomas we found an RR 
of 2.63 for CRC in families of at least 2 probands with melanoma and at least one with multiple melanomas17. 
Cutaneous lesions were associated with MUTYH mutations but no melanomas were reported nor are such muta-
tions regarded as melanoma predisposing genes18, 19. For eye cancer melanoma is the most common histology but 
RRs did not reach statistical significance for association with CRC. Cutaneous and ocular melanomas are known 
to share familial risks and BAP1 gene mutations predispose to both cancers17, 18, 20.
In summary, applying the novel approach of testing familial risks in families with increasing numbers of 
discordant cancers we found persuasive evidence that at least melanoma, thyroid and eye cancers were related to 
CRC outside known CRC-related syndromes. A number of other cancers associated with CRC in single analyses 
and independent studies are required to assess the relevance of such findings.
Methods
Terms HNPCC and Lynch syndrome were initially used interchangeably until Jass defined Lynch syndrome as a 
disease with a proven mismatch repair gene mutation while HNPCC was a clinical definition based on e.g., the 
Amsterdam criteria21. It is well known that there are HNPCC families lacking mismatch repair gene defects22, 23. 
As our analyses were based entirely on clinical data we used the term HNPCC.
Swedish Family-Cancer Database was created by combining the Multi-Generation Register, national Cancer 
Registry (started in 1958), and census data. The Database includes all Swedish people born after 1932 (offspring 
generation) and their biological parents (parental generation). The Database was updated in 2015 containing 15.7 
million individuals among which 1.8 million had a cancer diagnosis by the end of 2012.
The 3-digital codes of the 7th revision of the International Classification of Diseases (ICD-7) were used to 
identify the 35 most common primary cancers and cancer of unknown primary (CUP). For identification of 
HNPCC families, information on multiple primary cancers was used13. If at least one family member in a nuclear 
family had a double primary consisting of CRC and any of the following cancers: endometrium, ovary, small 
intestine, pancreas, brain, liver, kidney and bladder, the family was regarded as a likely HNPCC family. For liver 
and kidney cancers the exclusion may be excessive because only rare hepatobiliary tract cancer and cancer of 
renal pelvis are considered part of HNPCC14. On the other hand, stomach cancers were not used as an exclusion 
criterion although it may also be included in HNPCC9. The order of multiple primaries was not crucial but CRC 
was required to be present.
The follow-up for cancer in the offspring generation was started from the beginning of 1958, the birth year, or 
the immigration year, whichever came latest. Follow-up was terminated when a person was diagnosed with can-
cer, emigrated or died, or at the end of 2012, whichever came first. The number of FDRs (parents and/or siblings) 
who were affected with cancer was considered as a family history. Incidence rates could be obtained by counting 
cancer cases and person-years according to family history.
RRs, calculated for the offspring generation, were used as a measure of familial risk by comparing incidence 
rates for persons with affected relatives (referred to as probands) to incidence rates for those whose probands 
had no cancer. In the two-way comparison, firstly, RR for cancer X was calculated when family history was CRC, 
and then in the reverse order RR for CRC was calculated when family history was cancer X. For parents and 
offspring (large majority of familial cases) these comparisons are independent but for siblings the pairs of cases 
are the same. Significant results in two-way analyses provide support for a true association but a lacking two-way 
association is no strong evidence against an association because age distributions and case numbers may differ 
between two-way analyses.
Poisson regression modeling was employed to estimate RRs and corresponding confidence intervals (CI) for 
5%, 1% and 0.1% significance levels. Trend tests were performed by modeling the number of familial cancers as 
a continuous covariate. Potential confounders, including sex, age group (5-year bands), period (5-year bands), 
socioeconomic status (blue collar worker, white collar worker, farmer, private, professional, or other/unspecified), 
residential area (large cities, South Sweden, North Sweden, or unspecified) were added to the model as covariates. 
SAS version 9.4 was used to perform the statistical analysis.
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines.
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